The link between disturbances in kynurenine pathway (KP) metabolism and Huntington’s disease (HD) pathogenesis has been explored for a number of years. Several novel genetic and pharmacological tools have recently been developed to modulate key regulatory steps in the KP such as the reaction catalyzed by the enzyme kynurenine 3-monooxygenase (KMO). This insight has offered new options for exploring the mechanistic link between this metabolic pathway and HD, and provided novel opportunities for the development of candidate drug-like compounds. Here, we present an overview of the field, focusing on some novel approaches for interrogating the pathway experimentally.
CITATION STYLE
Sathyasaikumar, K. V., Breda, C., Schwarcz, R., & Giorgini, F. (2018). Assessing and modulating kynurenine pathway dynamics in Huntington’s disease: Focus on kynurenine 3-monooxygenase. In Methods in Molecular Biology (Vol. 1780, pp. 397–413). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7825-0_18
Mendeley helps you to discover research relevant for your work.